Advertisement

ETHZilla Corporation Common Stock ATNF

Set alert

Price alert · ATNF

All alert types
7.04 0.00 0.00%

At close · Aug 15

6.29 Day range 7.24

52-week range unavailable

YTD
+286.81%
1 year
+264.77%
Open
6.84
Prev close
7.04
Mkt cap
5.73M
Vol
11.63M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
6.29
High
7.24
Forward P/E
-6.30
Beta
0.25
Short ratio
0.03
Inst. own
3.45%
Dividend
0.00
Ex-div date
50-d avg
2.87
200-d avg
2.20
1y target
0.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for ATNF has not been loaded yet. Try again in a moment.

Key statistics

Market cap
5.73M
Enterprise value
1.72M
Trailing P/E
0.36
Forward P/E
-6.30
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
7.98
Beta
0.25
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-4.45M
Total cash
1.15M
Total debt
442.29K
Return on equity
-398.58%
Shares outstanding
1.98M
Short % of float
13.68%
50-day average
2.87
200-day average
2.20

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
ATNF Revenue — quarterly 0
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025
ATNF Net income — quarterly -1.73M
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025
ATNF EPS — quarterly -0.30
2021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 2025

About ETHZilla Corporation Common Stock

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ATNF — it syncs with the Stock Master app.

Insider holders

ATNF insider holders
InsiderRelationLatest transactionDateShares held
FELDMANN MARCDirectorStock Award(Grant)Dec 27, 2023250,874
GOLD LAWRENCE MDirectorStock Award(Grant)Aug 31, 202324,745
MARRONE PAMELA GDirectorStock Award(Grant)Aug 31, 202334,857
MCGOVERN DONALD A JR.DirectorStock Award(Grant)Aug 31, 202355,285
PAMIR OZANChief Financial OfficerPurchaseMay 17, 20238,983
RAY RUSSELL TDirectorStock Award(Grant)Aug 31, 202324,409

Institution ownership

ATNF institution ownership
Holder% heldSharesValueReported
Virtu Financial LLC0.71%14,08840.85KSep 29, 2024
UBS Group AG0.35%6,84719.86KSep 29, 2024
Tower Research Capital LLC (TRC)0.12%2,3356.77KSep 29, 2024
Blackrock Inc.0.03%5641.64KSep 29, 2024
Bank of America Corporation0.00%720Sep 29, 2024
Semmax Financial Advisors Inc.0.00%12Sep 29, 2024

Fund ownership

ATNF fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.24%4,64913.48KOct 30, 2024
Vanguard Extended Market Index Fund0.13%2,5217.31KSep 29, 2024
Fidelity Total Market Index Fund0.01%102295Oct 30, 2024
Fidelity Series Total Market Index Fund0.00%77223Oct 30, 2024
Advertisement